Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke

Bibliography

• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245-54
   PubMed Web of Science ®Google Scholar
• Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240-9
   PubMed Web of Science ®Google Scholar
• Emberson J, Lees KR, Lyden P, et al. for the Stroke Thrombolysis Trialists’ Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384(9958):1929-35
   PubMed Web of Science ®Google Scholar
• Koennecke HC, Belz W, Berfelde D, et al. for the Berlin Stroke Register Investigators. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011;77:965-72
   PubMed Web of Science ®Google Scholar
• Finlayson O, Kapral M, Hall R, et al. on behalf of the Investigators of the Registry of the Canadian Stroke Network. Risk factors, inpatient care, and outcomes of pneumonia after ischemic stroke. Neurology 2011;77:1338-45
   PubMed Web of Science ®Google Scholar
• Westendorp WF, Nederkoorn PJ, Vermeij JD, et al. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol 2011;11:110
   PubMed Web of Science ®Google Scholar
• Emsley HC, Smith CJ, Gavin CM, et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003;139:93-101
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Pinto A, Corrao S, et al. Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. Atherosclerosis 2009;203:503-8
   PubMed Web of Science ®Google Scholar
• Emsley HC, Smith CJ, Gavin CM, et al. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol 2007;7:5
   PubMedGoogle Scholar
• Haeusler KG, Schmidt WU, Föhring F, et al. Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis 2008;25:50-8
   PubMed Web of Science ®Google Scholar
• Prass K, Meisel C, Höflich C, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003;198:725-36
   PubMed Web of Science ®Google Scholar
• Smith CJ, Emsley HC, Udeh CT, et al. Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine 2012;58:384-9
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001;32:917-24
   PubMed Web of Science ®Google Scholar
• Smith CJ, Emsley HC, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004;4:2
   PubMed Web of Science ®Google Scholar
• Hug A, Dalpke A, Wieczorek N, et al. Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 2009;40:3226-32
   PubMed Web of Science ®Google Scholar
• Scherbakov N, Dirnagl U, Doehner W. Body weight after stroke: lessons from the obesity paradox. Stroke 2011;42:3646-50
   PubMed Web of Science ®Google Scholar
• Norris JW, Hachinski VC. High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed) 1986;292:21-3
   PubMed Web of Science ®Google Scholar
• The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-8
   PubMed Web of Science ®Google Scholar
• Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology 2001;57:1428-34
   PubMed Web of Science ®Google Scholar
• Bogousslavsky J, Victor SJ, Salinas EO, et al. European-Australian Fiblast (Trafermin) in Acute Stroke Group. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 2002;14:239-51
   PubMed Web of Science ®Google Scholar
• Krams M, Lees KR, Hacke W, et al. for the ASTIN Study. Acute stroke therapy by inhibition of neutrophils (ASTIN). An adaptive dose-response study of UK-279,276 in acute ischhemic stroke. Stroke 2003;34:2543-8
   PubMed Web of Science ®Google Scholar
• Shauib A, Lees KR, Lyden P, et al.SAINT II. Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-71
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Weissenborn K, Prange H, et al. EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:e647-56
   PubMed Web of Science ®Google Scholar
• den Hertog HM, van der Worp HB, van Gemert HM, et al. PAIS Investigators. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol 2009;8:434-40
   PubMed Web of Science ®Google Scholar
• Dávalos A, Alvarez-Sabín J, Castillo J, et al. International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012;380:349-57
   PubMed Web of Science ®Google Scholar
• Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial (NeuMAST). Available from: http://clinicaltrials.gov/show/NCT00930020
   Google Scholar
• Kohler E, Prentice DA, Bates TR, et al. Intravenous minocycline in acute stroke: a randomized, controlled pilot study and meta-analysis. Stroke 2013;44:2493-9
   PubMed Web of Science ®Google Scholar
• Ringelstein EB, Thijs V, Norrving B, et al. AXIS 2 Investigators. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke 2013;44:2681-7
   PubMed Web of Science ®Google Scholar
• Ginsberg MD, Palesch YY, Hill MD, et al. ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol 2013;12:1049-58
   PubMed Web of Science ®Google Scholar
• A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke. Available from: https://clinicaltrials.gov/ct2/show/NCT00046761?term=arundic+acid&rank=6
   Google Scholar
• Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8
   PubMed Web of Science ®Google Scholar
• Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598-606
   PubMed Web of Science ®Google Scholar
• Fisher M; for the Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies. Stroke Therapy Academic Industry Roundtable 3. Stroke 2003;34:1539-46
   PubMed Web of Science ®Google Scholar
• Fisher M; for the Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies. Stroke Therapy Academic Industry Roundtable. Stroke 2005;36:1808-13
   PubMed Web of Science ®Google Scholar
• Fisher M, Feuerstein G, Howells DW, et al. for the STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-50
   PubMed Web of Science ®Google Scholar
• Saver JL, Albers GW, Dunn B, et al. for the STAIR VI Consortium. Stroke therapy academic industry roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009;40:2594-600
   PubMed Web of Science ®Google Scholar
• Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007;27:894-908
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Hills NK, Saver JL, et al. for the California Acute Stroke Prototype Registry Investigators. Frequency and determinants of pneumonia and urinary tract infection during stroke hospitalization. J Stroke Cerebrovasc Dis 2006;15:209-13
   PubMedGoogle Scholar
• Minnerup J, Schäbitz W. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 2009;6:43-52
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50
   PubMed Web of Science ®Google Scholar
• Boutin H, LeFeuvre RA, Horai R, et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001;21:5528-34
   PubMed Web of Science ®Google Scholar
• Denes A, Pinteaux E, Rothwell NJ, et al. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis 2011;32:517-27
   PubMed Web of Science ®Google Scholar
• Denes A, Wilkinson F, Bigger B, et al. Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in mice. Dis Model Mech 2013;6:1043-8
   PubMed Web of Science ®Google Scholar
• Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005;5:629-40
   PubMed Web of Science ®Google Scholar
• McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 2007;27:4403-12
   PubMed Web of Science ®Google Scholar
• Pradillo JM, Denes A, Greenhalgh AD, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab 2012;32:1810-19
   PubMed Web of Science ®Google Scholar
• Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab 2011;31:439-47
   PubMed Web of Science ®Google Scholar
• Greenhalgh AD, Galea J, Denes A, et al. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol 2010;160:153-9
   PubMed Web of Science ®Google Scholar
• Singh N, Hopkins SJ, Hulme S, et al. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation 2014;11:1
   PubMed Web of Science ®Google Scholar
• Banwell V, Sena ES, Macleod MR. Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis 2009;18:269-76
   PubMed Web of Science ®Google Scholar
• Emsley HCA, Smith CJ, Georgiou RF, et al. for the IL-1ra in Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;76:1366-72
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5
   PubMed Web of Science ®Google Scholar
• Kawashima S, Yamashita T, Miwa Y, et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003;34:157-63
   PubMed Web of Science ®Google Scholar
• Kilic U, Bassetti CL, Kilic E, et al. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Neuroscience 2005;134:901-6
   PubMed Web of Science ®Google Scholar
• Prinz V, Laufs U, Gertz K, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008;39:433-8
   PubMed Web of Science ®Google Scholar
• Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003;23:322-7
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-51
   PubMed Web of Science ®Google Scholar
• Baryan H, Vail A, Allan SM, et al. Systematic review and meta-analysis of the efficacy of statins in experimental stroke. Int J Stroke 2012;7:150-6
   PubMed Web of Science ®Google Scholar
• Krauth D, Anglemyer A, Philipps R, et al. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol 2014;12:e1001770
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Yokoi H, Nohara R, Daida H, et al. for the Justification of Atherosclerosis Regression Treatment (JART) Investigators. Changes in carotid intima-media thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin. Subanalysis of the JART study. Int Heart J 2014;55:146-52
   PubMed Web of Science ®Google Scholar
• Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering – are they clinically relevant? Eur Heart J 2003;24:225-48
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-201
   PubMed Web of Science ®Google Scholar
• Antonopoulos AS, Margaritis M, Shirodaria C, et al. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 2012;108:840-8
   PubMed Web of Science ®Google Scholar
• Di Napoli M, Papa F. Inflammation, statins, and outcome after ischemic stroke. Stroke 2001;32:2446-7
   PubMed Web of Science ®Google Scholar
• Montecucco F, Mach F. Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2009;23:389-400
   PubMed Web of Science ®Google Scholar
• Montecucco F, Quercioli A, Mirabelli-Badenier M, et al. Statins in the treatment of acute ischemic stroke. Curr Pharm Biotechnol 2012;13:68-76
   PubMed Web of Science ®Google Scholar
• Chróinín N, Asplund K, Åsberg S, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational and randomized trials. Stroke 2013;44:448-56
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Amarenco P, Zivin J, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009;40:3526-31
   PubMed Web of Science ®Google Scholar
• Montaner J, Chacón P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008;15:82-90
   PubMed Web of Science ®Google Scholar
• Szczepańska-Szerej A, Kurzepa J, Wojczal J, et al. Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke. Pharmacol Rep 2007;59:94-7
   PubMed Web of Science ®Google Scholar
• Kurzepa J, Bielewicz J, Bartosik-Psujek H, et al. Simvastatin inhibits the increase in serum tau protein levels in the acute phase of ischemic stroke. Pharmacol Rep 2008;60:1014-18
   PubMed Web of Science ®Google Scholar
• Elkind MS, Sacco R, MacArthur RB, et al. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis 2009;28:266-75
   PubMed Web of Science ®Google Scholar
• Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): a Phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke. The Internet Stroke Center Trials Registry. Available from: http://www.strokecenter.org/trials/clinicalstudies/neuroprotection-with-statin-therapy-for-acute-recovery-trial-neu-starta-phase-2-safety-and-pilot-efficacy-study-of-lovastatin-for-the-treatment-of-acute-ischemic-stroke-spotrias/references
   Google Scholar
• Muscari A, Puddu GM, Santoro N, et al. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial. Clin Neuropharmacol 2011;34:141-7
   PubMed Web of Science ®Google Scholar
• Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011;69:759-77
   PubMed Web of Science ®Google Scholar
• Rolland WB, Lekic T, Krafft PR, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol 2013;241:45-55
   PubMed Web of Science ®Google Scholar
• Campos F, Qin T, Castillo J, et al. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke 2013;44:505-11
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang C, Tao W, et al. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci 2013;123:163-9
   PubMed Web of Science ®Google Scholar
• Kraft P, Göb E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke 2013;44:3202-10
   PubMed Web of Science ®Google Scholar
• Ward MD, Jones DE, Goldman MD. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf 2014;13:989-98
   PubMed Web of Science ®Google Scholar
• Espinera AR, Ogle ME, Gu X, et al. Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience 2013;247:1-11
   PubMed Web of Science ®Google Scholar
• Wang SS, Wang YG, Chen HY, et al. Expression of genes encoding cytokines and corticotropin releasing factor are altered by citalopram in the hypothalamus of post-stroke depression rats. Neuro Endocrinol Lett 2013;34:773-9
   PubMed Web of Science ®Google Scholar
• Rodriguez-Grande B, Blackabey V, Gittens B, et al. Loss of substance P and inflammation precede delayed neurodegeneration in the substantia nigra after cerebral ischemia. Brain Behav Immun 2013;29:51-61
   PubMed Web of Science ®Google Scholar
• Kronenberg G, Balkaya M, Prinz V, et al. Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biol Psychiatry 2012;72:273-81
   PubMed Web of Science ®Google Scholar
• Wang T, Lv P, Jin W, et al. Protective effect of donepezil hydrochloride on cerebral ischemia/reperfusion injury in mice. Mol Med Rep 2014;9:509-14
   PubMed Web of Science ®Google Scholar
• Min D, Mao X, Wu K, et al. Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. Neurosci Lett 2012;510:29-33
   PubMed Web of Science ®Google Scholar
• Fujiki M, Kobayashi H, Uchida S, et al. Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats. Brain Res 2005;1043:236-41
   PubMed Web of Science ®Google Scholar
• Yuan H, Wang WP, Feng N, et al. Donepezil attenuated oxygen-glucose deprivation insult by blocking Kv2.1 potassium channels. Eur J Pharmacol 2011;657:76-83
   PubMed Web of Science ®Google Scholar
• Akasofu S, Sawada K, Kosasa T, et al. Donepezil attenuates excitotoxic damage induced by membrane depolarization of cortical neurons exposed to veratridine. Eur J Pharmacol 2008;588:189-97
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Egashira N, Hatip-Al-Khatib I, et al. Cerebral ischemia combined with beta-amyloid impairs spatial memory in the eight-arm radial maze task in rats. Brain Res 2006;1097:216-23
   PubMed Web of Science ®Google Scholar
• Lee JH, Park SY, Shin YW, et al. Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats. Brain Res 2007;1185:246-55
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Ohki K, Saito M, et al. Histological protection by donepezil against neurodegeneration induced by ischemia-reperfusion in the rat retina. J Pharmacol Sci 2010;112:327-35
   PubMed Web of Science ®Google Scholar
• Yoshiyama Y, Kojima A, Ishikawa C, et al. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 2010;22:295-306
   PubMed Web of Science ®Google Scholar
• Cheyuo C, Jacob A, Wu R, et al. The parasympathetic nervous system in the quest for stroke therapeutics. J Cereb Blood Flow Metab 2011;31:1187-95
   PubMed Web of Science ®Google Scholar
• Barrett KM, Brott TG, Brown RDJr, et al. Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) Study Group. Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial. J Stroke Cerebrovasc Dis 2011;20:177-82
   PubMed Web of Science ®Google Scholar
• Akdemir G, Ergungor MF, Sezer M, et al. Therapeutic efficacy of intraventricular cyclosporine A and methylprednisolone on a global cerebral ischemia model in rats. Neurol Res 2005;27:827-34
   PubMed Web of Science ®Google Scholar
• Chauhan A, Sharma U, Jagannathan NR, et al. Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats. Behav Brain Res 2011;225:603-9
   PubMed Web of Science ®Google Scholar
• Cho TH, Aguettaz P, Campuzano O, et al. Pre- and post-treatment with cyclosporine A in a rat model of transient focal cerebral ischaemia with multimodal MRI screening. Int J Stroke 2013;8:669-74
   PubMed Web of Science ®Google Scholar
• Wakita H, Tomimoto H, Akiguchi I, et al. Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion. Stroke 1995;26:1415-22
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Isshiki A, Watanabe Y, et al. Restricted clinical efficacy of cyclosporin A on rat transient middle cerebral artery occlusion. Life Sci 2002;72:591-600
   PubMed Web of Science ®Google Scholar
• Gill RS, Lee TF, Liu JQ, et al. Cyclosporine treatment reduces oxygen free radical generation and oxidative stress in the brain of hypoxia-reoxygenated newborn piglets. PLoS One 2012;7:e40471
   Google Scholar
• Peterson JW, Nishizawa S, Hackett JD, et al. Cyclosporine A reduces cerebral vasospasm after subarachnoid hemorrhage in dogs. Stroke 1990;21:133-7
   PubMed Web of Science ®Google Scholar
• Waring WS. Uric acid: an important antioxidant in acute ischaemic stroke. QJM 2002;95:691-3
   PubMed Web of Science ®Google Scholar
• Kanemitsu H, Tamura A, Kirino T, et al. Allopurinol inhibits uric acid accumulation in the rat brain following focal cerebral ischemia. Brain Res 1989;499:367-70
   PubMed Web of Science ®Google Scholar
• Tayag EC, Nair SN, Wahhab S, et al. Cerebral uric acid increases following experimental traumatic brain injury in rat. Brain Res 1996;733:287-91
   PubMed Web of Science ®Google Scholar
• Yu ZF, Bruce-Keller AJ, Goodman Y, et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613-25
   PubMed Web of Science ®Google Scholar
• Romanos E, Planas AM, Amaro S, et al. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007;27:14-20
   PubMed Web of Science ®Google Scholar
• Glantz L, Avramovich A, Trembovler V, et al. Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia. Exp Neurol 2005;192:117-24
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kouzaki H, Kita H. Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. J Immunol 2010;184:6350-8
   PubMed Web of Science ®Google Scholar
• Kono H, Chen CJ, Ontiveros F, et al. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 2010;120:1939-49
   PubMed Web of Science ®Google Scholar
• Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One 2011;6:e19901
   PubMed Web of Science ®Google Scholar
• Savage CD, Lopez-Castejon G, Denes A, et al. NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front Immunol 2012;3:288
   PubMed Web of Science ®Google Scholar
• Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002;33:1048-52
   PubMed Web of Science ®Google Scholar
• Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951
   Web of Science ®Google Scholar
• Amaro S, Soy D, Obach V, et al. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 2007;38:2173-5
   PubMed Web of Science ®Google Scholar
• Amaro S, Obach V, Cervera A, et al. Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol 2009;256:651-6
   PubMed Web of Science ®Google Scholar
• Chamorro A, Amaro S, Castellanos M, et al. URICO-ICTUS Investigators. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014;13:453-60
   PubMed Web of Science ®Google Scholar
• Coisne C, Mao W, Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 2009;182:5909-13
   PubMed Web of Science ®Google Scholar
• Liesz A, Zhou W, Mracsko E, et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 2011;134:704-20
   PubMedGoogle Scholar
• Relton JK, Sloan KE, Frew EM, et al. Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke 2001;32:199-205
   PubMed Web of Science ®Google Scholar
• Langhauser F, Kraft P, Gob E, et al. Blocking of alpha4 integrin does not protect from acute ischemic stroke in mice. Stroke 2014;45:1799-806
   PubMed Web of Science ®Google Scholar
• Ye R, Zhao G, Liu X. Ginsenoside Rd for acute ischemic stroke: translating from bench to bedside. Expert Rev Neurother 2013;13:603-13
   PubMed Web of Science ®Google Scholar
• Ye R, Kong X, Yang Q, et al. Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window. Neurotherapeutics 2011;8:515-25
   PubMed Web of Science ®Google Scholar
• Ye R, Yang Q, Kong X, et al. Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats. Neurochem Int 2011;58:391-8
   PubMed Web of Science ®Google Scholar
• Hu G, Wu Z, Yang F, et al. Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-κB nuclear accumulation by inhibiting poly(ADP-ribose) polymerase-1 after focal cerebral ischemia in rats. Neurol Sci 2013;34:2101-6
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li HQ, Lu L, et al. Ginsenoside Rg1 provides neuroprotection against blood brain barrier disruption and neurological injury in a rat model of cerebral ischemia/reperfusion through downregulation of aquaporin 4 expression. Phytomedicine 2014;21:998-1003
   PubMed Web of Science ®Google Scholar
• Liu X, Xia J, Wang L, et al. Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial. Eur J Neurol 2009;16:569-75
   PubMed Web of Science ®Google Scholar
• Liu X, Wang L, Wen A, et al. Ginsenoside-Rd improves outcome of acute ischaemic stroke - a randomized, double-blind, placebo-controlled, multicenter trial. Eur J Neurol 2012;19:855-63
   PubMed Web of Science ®Google Scholar
• Ahmad A, Khan MM, Javed H, et al. Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat. Mol Cell Biochem 2012;367:215-25
   PubMed Web of Science ®Google Scholar
• Xiao B, Bi FF, Hu YQ, et al. Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats. Neurotox Res 2007;12:155-62
   PubMed Web of Science ®Google Scholar
• Yagi K, Kitazato KT, Uno M, et al. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009;40:626-31
   PubMed Web of Science ®Google Scholar
• Zhang W, Sato K, Hayashi T, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res 2004;26:342-8
   PubMed Web of Science ®Google Scholar
• Srinivasan K, Sharma SS. Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. Basic Clin Pharmacol Toxicol 2011;110:133-40
   PubMed Web of Science ®Google Scholar
• Kern R, Nagayama M, Toyoda K, et al. Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis 2013;35:402-18
   PubMed Web of Science ®Google Scholar
• Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222-9
   PubMed Web of Science ®Google Scholar
• Zhang M, Xu L, Deng L, et al. Efficacy and safety evaluation of edaravone injection in treatment of acute cerebral infarction: a multicentre, double-blind, and randomized controlled clinical trial. Chinese J New Drugs Clin Remedies 2007;26:105-8
   Google Scholar
• Zhou M, Yang J, He L. Randomized controlled trial of edaravone injection in the treatment of acute cerebral infarction. Mod Prev Med 2007;34:966-8
   Google Scholar
• Shinohara Y, Saito I, Kobayashi S, et al. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis 2009;27:485-92
   PubMed Web of Science ®Google Scholar
• Feng S, Yang Q, Liu M, et al. Edaravone for acute ischaemic stroke. Cochrane Database Syst Rev 2011(12):CD007230
   Google Scholar
• Kaste M, Murayama S, Ford GA, et al. MCI-186 study group. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis 2013;36:196-204
   PubMed Web of Science ®Google Scholar
• O’Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77
   PubMed Web of Science ®Google Scholar
• Smith CJ, Lawrence CB, Rodriguez-Grande B, et al. The immune system in stroke: clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol 2013;8:867-87
   PubMed Web of Science ®Google Scholar
• Bailey EL, McCulloch J, Sudlow C, et al. Potential animal models of lacunar stroke: a systematic review. Stroke 2009;40:e451-8
   Web of Science ®Google Scholar
• Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 2008;39:929-34
   PubMed Web of Science ®Google Scholar
• Dirnagl U, Hakim A, Macleod M, et al. A concerted appeal for international cooperation in preclinical stroke research. Stroke 2013;44:1754-60
   PubMed Web of Science ®Google Scholar
• Albers GW, Goldstein LB, Hess DC, et al. STAIR VII Consortium. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 2011;42:2645-50
   PubMed Web of Science ®Google Scholar
• Yeatts SD. Novel approaches to phase I, II and III trials. Stroke 2013;44:s116-18
   Google Scholar
• Bath PM, Lees KR, Schellinger PD, et al. European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke 2012;43:1171-8
   PubMed Web of Science ®Google Scholar
• Nair SB, Dileep A, Rajanikant GK. Nanotechnology based diagnostic and therapeutic strategies for neuroscience with special emphasis on ischemic stroke. Curr Med Chem 2012;19:744-56
   PubMed Web of Science ®Google Scholar